Advertisement

Advertisement
Leukemia

Conditioning Intensity for Allogeneic Transplantation in Patients With AML

In a study reported in the Journal of Clinical Oncology, Hourigan et al found that reduced-intensity conditioning for allogeneic hematopoietic cell transplantation was associated with poorer outcomes vs myeloablative conditioning in patients with acute myeloid leukemia (AML) who had genomic evidence of residual disease.

Hepatobiliary Cancer

Treatment Resistance and Novel Therapies in FGFR-Mutated Cholangiocarcinoma

A new study has shown how resistance to fibroblast growth factor receptor (FGFR) inhibitor treatment develops in patients with cholangiocarcinoma and suggests that adding another therapy at the time of disease progression might resensitize tumor cells to initial therapy. These findings were published by Krook et al in Molecular Cancer Therapeutics.

Myelodysplastic Syndromes
Gynecologic Cancers
Bladder Cancer
Gastrointestinal Cancer

Luspatercept in Transfusion-Dependent Lower-Risk Myelodysplastic Syndromes

We’ll start off this week on The ASCO Post Podcast by discussing results from the MEDALIST trial of luspatercept in transfusion-dependent lower-risk myelodysplastic syndromes...

 

 

 


Advertisement
Integrative Oncology

Society for Integrative Oncology’s 16th International Conference

The Society for Integrative Oncology (SIO) hosted its 16th International Conference in New York City, October 19-21, 2019, in partnership with Memorial Sloan Kettering Cancer Center (MSK). The conference theme, “Advancing the Science and Art of Integrative Oncology,” focused on deepening the understanding of the role that integrative therapies play in cancer care and on promoting the art of humanistic care, which recognizes the values, preferences, and rights of patients with cancer and their families.

Skin Cancer

Different Doses of Adjuvant Ipilimumab vs High-Dose Interferon Alfa-2b in Patients With Resected High-Risk Melanoma

As reported in the Journal of Clinical Oncology by Tarhini et al, the phase III Intergroup E1609 trial has shown an overall survival advantage with adjuvant ipilimumab at 3 mg/kg—but not at 10 mg/kg—vs high-dose interferon alfa-2b in patients with resected high-risk cutaneous melanoma. The investigators noted that this outcome marks the first time a survival benefit of adjuvant treatment has been observed against an active comparator in this setting.

Advertisement




More Top Stories

Breast Cancer

Tari A. King, MD, on Molecular Differences Between Primary and Metastatic Breast Tumors

Lung Cancer

Impact of the NCI Cell-Line Database: A Testament to Patient Altruism

In an homage to the gracious patients who provided biospecimens and to the dedicated researchers who have tended and studied the derived cell lines, James L. Mulshine, MD, of the Center for Healthy Aging, Department of Internal Medicine, Rush University, and colleagues have described the impact of...

Advertisement

Impact of Genes on Total Number and Type of Nevi

A study by Duffy et al in the Journal of Investigative Dermatology reported on specific gene variations affecting the number and types of moles on the body and their role in causing skin cancer.  “The goal was to investigate the genetic underpinnings of different mole classes, or...

Skin Cancer
Immunotherapy

Paolo A. Ascierto, MD, on Melanoma: Results From CheckMate 238 on Adjuvant Nivolumab vs Ipilimumab

Leukemia

Conditioning Intensity for Allogeneic Transplantation in Patients With AML

In a study reported in the Journal of Clinical Oncology, Hourigan et al found that reduced-intensity conditioning for allogeneic hematopoietic cell transplantation was associated with poorer outcomes vs myeloablative conditioning in patients with acute myeloid leukemia (AML) who had genomic...

Breast Cancer

Dietary Supplement Use During Adjuvant Chemotherapy and Treatment Outcomes in Patients With Early Breast Cancer

As reported in the Journal of Clinical Oncology by Ambrosone et al, an analysis of the SWOG S0221 trial population suggests that use of antioxidant and nonantioxidant dietary supplements, but not multivitamins, before and during adjuvant chemotherapy may be associated with poorer treatment outcomes ...

Gemcitabine/Eribulin in Cisplatin-Ineligible Metastatic Urothelial Carcinoma

In the final analysis from a phase II California Cancer Consortium trial (NCI-9653) reported in the Journal of Clinical Oncology, Sadeghi et al found the combination of gemcitabine and eribulin showed activity in cisplatin-ineligible patients with metastatic urothelial carcinoma. Study Details...

Breast Cancer
Immunotherapy

Sara M. Tolaney, MD, MPH, on HER2-Positive Breast Cancer: ATEMPT Trial on T-DM1 vs Paclitaxel Plus Trastuzumab

Lung Cancer

Step Counts May Help Predict Treatment Outcomes for Patients With NSCLC

A new study suggests step counters could play a role in predicting outcomes for people undergoing chemoradiation therapy for lung cancer. These findings were published by Ohri et al in the International Journal of Radiation Oncology • Biology • Physics. “I consider step counts to be a new vital...

Advertisement

Deintensified Chemoradiotherapy for HPV-Associated Oropharyngeal Squamous Cell Carcinoma

In a phase II trial reported in the Journal of Clinical Oncology, Chera et al found that deintensified chemoradiotherapy produced favorable outcomes in human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma. Study Details In the multicenter trial, 114 patients were recruited...